Skip to main content

Part of UT Health San Antonio

Graduate School of Biomedical Sciences, UT Health San AntonioGraduate School of Biomedical Sciences, UT Health San Antonio

Part of UT Health San Antonio

Give
Search

Quicklinks

Commencement

  • Commencement 2021

Logins

  • Canvas
  • CourseLeaf
  • IMPACT
  • LiveMail
  • Syllabus Depot
  • My UT Health (Intranet)

Resources

  • COVID-19 Updates for Students
  • Enrolled Student Resources
  • Educational Resources
  • GSBS Data Request Form

 Close Quicklinks

 
Menu
  • About
  • Admissions
  • Programs
  • Research
  • Faculty
  • Student Life
  • Alumni

You are here

  • Faculty directory
  • Gregory Collins
Gregory Collins

Contact

210-567-4199

collinsg@uthscsa.edu

Programs

M.D./Ph.D. in South Texas Medical Scientist Training Program
Neuroscience
Ph.D. in Integrated Biomedical Sciences
Physiology and Pharmacology

Departments & Divisions

Department of Pharmacology

Institutes and Centers

  • Addiction Research, Treatment & Training Center
  • Center for Biomedical Neurosciences

Currently seeking Ph.D. students.

Gregory Collins, Ph.D.

Assistant Professor

Department of Pharmacology

Research in my laboratory is broadly aimed at investigating the determinants of drug-taking and drug-seeking behaviors. Accordingly, we utilize intravenous self-administration procedures to assess the degree to which factors such as age, diet, sex, and drug history influence (1) the acquisition of drug-taking, (2) the reinforcing effectiveness of drugs, and (3) the effectiveness of drug-associated stimuli to promote responding during periods in which the drug is no longer available. In addition to drug self-administration, we also utilize drug-discrimination procedures as well as video and radio-telemetric assessments of drug effects on cardiopulmonary activity, body temperature, locomotor activity, and other observable behaviors. These procedures are used to better characterize the pharmacologic profile of both drugs of abuse as well as candidate medications for the treatment of substance abuse.

Currently my laboratory is focused on three primary areas of research:

1 – Characterizing the abuse-related and toxic effects of drug mixtures. These studies employ quantitative approaches to determine whether the discriminative stimulus, reinforcing and cardiovascular effects of drugs are altered when they are administered in combination with other co-abused drugs. Examples include (1) “bath salts” preparations that often contain mixtures of multiple synthetic cathinones (e.g., MDPV and methylone), or synthetic cathinones mixed with other non-cathinone constituents, such as caffeine, and (2) mixtures of stimulants (e.g., cocaine, methamphetamine, MDPV) and opioids (e.g., heroin, fentanyl) which are becoming increasingly popular in the US, and are responsible for growing proportion of the total deaths resulting from drug overdose.

2 – Investigating factors that contribute to individual differences in substance use disorder (SUD)-related behaviors. These studies exploit a recently identified “high-responder” phenotype in rats self-administering MDPV, to determine factors (e.g., age, sex, impulsivity, pharmacologic and reinforcement histories, etc.) that might predict the development of high levels of drug-taking and/or drug-seeking, resistance to punishment of drug-taking, and other SUD-related behaviors.

3 – Development of candidate medications for (poly)substance use disorders. These studies use intravenous drug self-administration as well as reinstatement models to evaluate the effectiveness of potential pharmacotherapeutics to reduce drug-taking and drug-seeking, respectively. In addition to efforts aimed at repurposing drug already approved by the FDA for treating other conditions (e.g., the 5-HT2C receptor agonist, lorcaserin), we are also interested in evaluating mixtures of highly selective but experimental drugs with the ultimate goal of developing novel polypharmacy approaches to treating (poly)substance use disorders.

  • Professional Background

    Education

    • 2008 - Ph.D. - Pharmacology - University of Michigan Medical School

    Training

    • 2012 - Post-doctoral fellowship - Behavioral Neuroscience - McLean Hospital / Harvard Medical School
    • 2010 - Post-doctoral fellowship - Behavioral Pharmacology - University of Michigan Medical School

    Highlights

    JH Woods Early Career Award in Behavioral Pharmacology from ASPET – 2021

    Best Young Investigator Award from the International Union of Basic and Clinical Pharmacology (IUPHAR) – 2018

    American College of Neuropsychopharmacology Travel Award – 2013

  • Research & Grants

    Grants

    • Preclinical Psychopharmacology of Substance Abuse
    • Bath Salts: abuse-related and toxic effects
    • Repurposing drugs in mixtures to treat drug abuse
  • Publications

    • Discriminative stimulus effects of 3,4-methylenedioxypyrovalerone (MDPV) and structurally related synthetic cathinones.
    • MDPV self-administration in female rats: influence of reinforcement history.
    • Interactions between reinforcement history and drug-primed reinstatement: Studies with MDPV and mixtures of MDPV and caffeine.
    • Influence of Contingent and Noncontingent Drug Histories on the Development of High Levels of MDPV Self-Administration.
    • Impact of Morphine Dependence and Withdrawal on the Reinforcing Effectiveness of Fentanyl, Cocaine, and Methamphetamine in Rats.
    • Interactions between impulsivity and MDPV self-administration in rats.
    • Application of dose-addition analyses to characterize the abuse-related effects of drug mixtures.
    • Self-administration of the synthetic cathinones 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (α-PVP) in
    • Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys.
    • Behavioral economic analysis of the reinforcing effects of "bath salts" mixtures: studies with MDPV, methylone, and caffeine in
    • Modeling Stimulant and Opioid Co-use in Rats Provided Concurrent Access to Methamphetamine and Fentanyl.
    • Relative reinforcing effects of cocaine and 3,4-methylenedioxypyrovalerone (MDPV) under a concurrent access self-administration

    My Bibliography 

    Google Scholar

Map image of UT Health San Antonio location
UT Health San Antonio
Graduate School of Biomedical Sciences

7703 Floyd Curl Drive

San Antonio, TX 78229

210-567-3709

gsbs@uthscsa.edu

  • About us
  • Contact us
  • Maps & directions

We make lives better ®

The University of Texas Health Science Center at San Antonio, also called UT Health San Antonio, is a leading academic health center with a mission to make lives better through excellence in advanced academics, life-saving research and comprehensive clinical care including health, dental and cancer services.

Web Privacy | Links from websites affiliated with UT Health's website (uthscsa.edu) to other websites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites. The content on this website is intended to be used for informational purposes only. Health information on this site is not meant to be used to diagnose or treat conditions. Consult a health care provider if you are in need of treatment.